Stefano Lancellotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6267212/publications.pdf

Version: 2024-02-01

44 papers	1,469 citations	361045 20 h-index	315357 38 g-index
44 all docs	44 docs citations	44 times ranked	2106 citing authors

#	Article	IF	Citations
1	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. Journal of Hepatology, 2009, 51, 682-689.	1.8	409
2	High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism. Diabetes, 2010, 59, 1496-1505.	0.3	110
3	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB Journal, 2010, 24, 3970-3980.	0.2	75
4	Congenital Prothrombin Deficiency: An Update. Seminars in Thrombosis and Hemostasis, 2013, 39, 596-606.	1.5	68
5	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	1.3	56
6	Congenital Prothrombin Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 367-381.	1.5	53
7	Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World Journal of Gastroenterology, 2011, 17, 594.	1.4	50
8	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Journal of Thrombosis and Haemostasis, 2015, 13, 1226-1237.	1.9	48
9	Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 391-402.	1.3	45
10	Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Internal and Emergency Medicine, 2016, 11, 959-967.	1.0	40
11	Effects of rehabilitation on quality of life in patients with chronic stroke. Brain Injury, 2008, 22, 451-456.	0.6	38
12	Fibrinogen-elongated Î³ Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors. Journal of Biological Chemistry, 2008, 283, 30193-30204.	1.6	34
13	Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clinical Science, 2011, 121, 555-564.	1.8	32
14	Mechanochemistry of von Willebrand factor. Biomolecular Concepts, 2019, 10, 194-208.	1.0	32
15	Ristocetin-induced self-aggregation of von Willebrand factor. European Biophysics Journal, 2010, 39, 1597-1603.	1.2	30
16	The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus. PLoS ONE, 2013, 8, e55396.	1.1	30
17	Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 19-28.	0.4	23
18	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. Blood, 2010, 116, 5371-5376.	0.6	23

#	Article	IF	Citations
19	Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461.	0.2	22
20	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Journal of Thrombosis and Haemostasis, 2011, 9, 1744-1751.	1.9	22
21	Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2019, 48, 528-531.	1.0	21
22	Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochemical Journal, 2012, 442, 423-432.	1.7	18
23	Kinetic study of von Willebrand factor self-aggregation induced by ristocetin. Biophysical Chemistry, 2009, 144, 101-107.	1.5	17
24	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTSâ€13. Journal of Thrombosis and Haemostasis, 2011, 9, 1620-1627.	1.9	17
25	Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. Current Medicinal Chemistry, 2011, 18, 2205-2214.	1.2	17
26	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€“control study. Blood Coagulation and Fibrinolysis, 2021, 32, 285-289.	0.5	16
27	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	1.9	15
28	PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013058.	0.5	15
29	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	1.8	14
30	Structure and Proteolytic Properties of ADAMTS13, A Metalloprotease Involved in the Pathogenesis of Thrombotic Microangiopathies. Progress in Molecular Biology and Translational Science, 2011, 99, 105-144.	0.9	12
31	ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Digestive and Liver Disease, 2022, 54, 1672-1680.	0.4	11
32	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 413-421.	1.0	9
33	Modeling ADAMTS13-von Willebrand Factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand Disease. Biophysical Chemistry, 2012, 160, 1-11.	1.5	7
34	Increased production of gliotoxin is related to the formation of biofilm byAspergillus fumigatus: an immunological approach. Pathogens and Disease, 2014, 70, 379-389.	0.8	7
35	Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. Frontiers in Pediatrics, 2021, 9, 743206.	0.9	7
36	Noncanonical type 2B von Willebrand disease associated with mutations in the VWF Dâ€²D3 and D4 domains. Blood Advances, 2020, 4, 3405-3415.	2.5	6

#	Article	IF	Citations
37	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	1.4	5
38	Effects of rehabilitation treatment on thyroid function. Clinical Endocrinology, 2009, 70, 644-649.	1.2	4
39	Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels. Thrombosis and Haemostasis, 2018, 118, 1701-1712.	1.8	4
40	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	0.7	4
41	Direct oral anticoagulants and therapeutic adherence: do not let your guard down. Acta Cardiologica, 2022, 77, 243-249.	0.3	3
42	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2010, 8, 416-418.	1.9	0
43	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. Blood, 2019, 134, 1178-1178.	0.6	0
44	The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis. , 2022, 1, .		0